BotableBook a call
FDA Warning Letter Explorer
FDA warning letter · Drugs

Tyrone L. McCall, M.D./Cornea Associates of Texas

Issued · Posted by FDA

Selected passages from the FDA letter

Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.

Passage 1

Failure to submit an Investigational New Drug application (IND) for the conduct of a clinical investigation with investigational new drugs that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].

Citations in the original letter

As cited in this historical letter, not a statement of current regulatory requirements.

  • 21 CFR 312.2
  • 21 CFR 312
  • 21 CFR 312.2(a)
  • 21 CFR 312.20(a)
  • 21 CFR 312.20
  • 21 CFR 312.2(b)(1)(i)